CanBas Co Ltd

TSE:4575 (Japan)  
円 486.00 (-1.01%) May 16
At Loss
P/B:
2.81
Market Cap:
円 8.87B ($ 57.25M)
Enterprise V:
円 7.25B ($ 46.81M)
Volume:
107.10K
Avg Vol (2M):
233.55K
Volume:
107.10K
At Loss
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for CanBas Co Ltd ( TSE:4575 ) from 2009 to May 16 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. CanBas stock (TSE:4575) PE ratio as of May 16 2024 is 0. More Details

CanBas Co Ltd (TSE:4575) PE Ratio (TTM) Chart

To

CanBas Co Ltd (TSE:4575) PE Ratio (TTM) Historical Data

Total 1219
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
CanBas PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-16 At Loss 2024-03-11 At Loss
2024-05-16 At Loss 2024-03-08 At Loss
2024-05-15 At Loss 2024-03-07 At Loss
2024-05-14 At Loss 2024-03-06 At Loss
2024-05-13 At Loss 2024-03-05 At Loss
2024-05-10 At Loss 2024-03-04 At Loss
2024-05-09 At Loss 2024-03-01 At Loss
2024-05-08 At Loss 2024-02-29 At Loss
2024-05-07 At Loss 2024-02-28 At Loss
2024-05-02 At Loss 2024-02-27 At Loss
2024-05-01 At Loss 2024-02-26 At Loss
2024-04-30 At Loss 2024-02-22 At Loss
2024-04-26 At Loss 2024-02-21 At Loss
2024-04-25 At Loss 2024-02-20 At Loss
2024-04-24 At Loss 2024-02-19 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-09 At Loss
2024-04-16 At Loss 2024-02-08 At Loss
2024-04-15 At Loss 2024-02-07 At Loss
2024-04-12 At Loss 2024-02-06 At Loss
2024-04-11 At Loss 2024-02-05 At Loss
2024-04-10 At Loss 2024-02-02 At Loss
2024-04-09 At Loss 2024-02-01 At Loss
2024-04-08 At Loss 2024-01-31 At Loss
2024-04-05 At Loss 2024-01-30 At Loss
2024-04-04 At Loss 2024-01-29 At Loss
2024-04-03 At Loss 2024-01-26 At Loss
2024-04-02 At Loss 2024-01-25 At Loss
2024-04-01 At Loss 2024-01-24 At Loss
2024-03-29 At Loss 2024-01-23 At Loss
2024-03-28 At Loss 2024-01-22 At Loss
2024-03-27 At Loss 2024-01-19 At Loss
2024-03-26 At Loss 2024-01-18 At Loss
2024-03-25 At Loss 2024-01-17 At Loss
2024-03-22 At Loss 2024-01-16 At Loss
2024-03-21 At Loss 2024-01-15 At Loss
2024-03-19 At Loss 2024-01-12 At Loss
2024-03-18 At Loss 2024-01-11 At Loss
2024-03-15 At Loss 2024-01-10 At Loss
2024-03-14 At Loss 2024-01-09 At Loss
2024-03-13 At Loss 2024-01-05 At Loss
2024-03-12 At Loss 2024-01-04 At Loss

CanBas Co Ltd (TSE:4575) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
CanBas Co Ltd focuses on the discovery and development of novel oncology drugs targeting the cell cycle. Its product, CBP501 the anticancer drug candidate is a modified synthetic peptide which enhances the efficacy of cisplatin without adding toxicity.